China Oral Hypoglyceimic Agents (OHAs) Industry Report, 2010

Report Summary

In 2009, the consumption of oral hypoglyceimic agents (OHAs) in China increased by 15.1% to RMB9.81 billion, accounting for approximately 5% of the world’s total. At present, China is a country with the most populous victims of diabetes, numbering as high as 92 million. But the treatment rate of this disease in China is, generally speaking, less than 30%. Coupled with the comparatively low per capita treatment payment, which is no more than 3% of that in the US, China will witness a huge potential in the OHAS market.

Among all the OHAS, patent medicines made by overseas pharmaceutical enterprises are hailed as “star products”. Many generic drugs exert little impact on patent medicines although they spring up. Meanwhile, foreign enterprises firmly control Chinese market by means of successful marketing strategy and product upgrading. In 2009, foreign enterprises occupied the top 5 by procurement value among the OHAS providers for China-based hospitals, making up as high as 60.8%. In particular, the ranking first Bayer, an acarbose producer, enjoyed a share of 29.4%. Of the top 10 enterprises by sales performance, Beijing Wanhui Double-Crane Pharmaceutical was the sole homegrown enterprise that produces gliquidone, with the market share no more than 3.7%.

The report not only probes into the status quo and competition pattern of the market, drug use of hospitals, and development tendency of OHAS industry, but also analytically elaborates the market segments as well as the operation and prospect of leading manufacturers, including 7 foreign enterprises and joint ventures playing dominant position in OHAS traditional western medicine varieties and Chinese patent medicine market as well as four Chinese counterparts of certain scale.

In addition, new OHAS varieties such as DDP-IV inhibitor and GLP-1 analog have been inflowing into Chinese market, including Januvia produced by Merck & Co Inc, and Onglyza by Bristol-Myers Squibb and AstraZeneca, which pose grave threat to traditional OHAS because of the good effect and little side-effect.

Table Of Contents

1. Overview of OHAS Industry
1.1 Definition
1.2 Classification

2. Status Quo and Prospect of Chinese OHAS Market
2.1 Status Quo of International Market
2.1.1 Market Size
2.1.2 Demand and Supply
2.2 Status Quo of Chinese Market
2.2.1 Market Size
2.2.2 Product Mix
2.3 Demand and Supply
2.4 Competition Pattern
2.5 Gross Margin of the Industry and Prices
2.6 Application of OHAS in Key Cities
2.6.1 Beijing
2.6.2 Shanghai
2.6.3 Guangzhou
2.6.4 Shenzhen
2.7 Policy Environment
2.8 Development Outlook
2.8.1 Huge Diabetic Population
2.8.2 Improvement in Treatment Rate and Expense of Diabetic Patients
2.8.3 Strong Growth of New OHAS Varieties

3. Key Varieties of OHAS
3.1 Acarbose
3.2 Metformin
3.3 Repaglinide
3.4 Glimepiride
3.5 Gliclazide
3.6 Glipizide
3.7 Gliquidone
3.8 Rosiglitazone
3.9 DDP-IV Inhibitor
3.10 GLP-1 Analog

4. Advantageous Foreign Enterprises in China OHAS Industry
4.1 Bayer
4.1.1 Profile
4.1.2 Operation
4.1.3 Operation in China
4.2 Bristol-Myers Squibb
4.2.1 Profile
4.2.2 Operation
4.2.3 Shanghai Bristol-Myers Squibb
4.2.4 Developments
4.3 Novonordisk
4.3.1 Profile
4.3.2 Operation
4.3.3 Operation in China
4.3.4 Developments
4.4 Sanofi-Aventis
4.4.1 Profile
4.4.2 Operation
4.4.3 Operation in China
4.5 Servier
4.5.1 Profile
4.5.2 Servier (Tianjin) Pharmaceutical
4.6 Pfizer
4.6.1 Profile
4.6.2 Operation in China
4.7 GlaxoSmithKline
4.7.1 Profile
4.7.2 Operation
4.7.3 Operation in China

5. Local Advantageous Enterprises in China OHAS Industry
5.1 Huadong Medicine
5.1.1 Profile
5.1.2 Operation
5.1.3 Developments
5.2 Wanbang Biopharmaceuticals
5.2.1 Profile
5.2.2 Operation
5.3 Double-Crane Pharmaceutical
5.3.1 Profile
5.3.2 Operation
5.3.3 Developments
5.4 Guangzhou Pharmaceutical
5.4.1 Profile
5.4.2 Operation